Granuloma Faciale Medication

Updated: Apr 05, 2021
  • Author: Robert A Schwartz, MD, MPH; Chief Editor: Dirk M Elston, MD  more...
  • Print
Medication

Medication Summary

Granuloma faciale is notoriously resistant to treatment; therefore, many different medical options available, with topical steroids and tacrolimus favored choices, sometimes enhanced with topical dapsone. [23, 24] Pulsed-dye laser [4, 25, 26] often produces resolution without scarring and should generally be tried before the patient is started on long-term medication. Other therapeutic options that have been tried and are reported to be effective include topical corticosteroid therapy, intralesional corticosteroid injections (without or in combination with 5-fljuorouracil, [27] ), intralesional gold injections, oral bismuth, antimalarials, isoniazid, oral potassium arsenite, p-aminobenzoic acid (PABA), calciferol, topical psoralen UV-A (PUVA), [28] intralesional rituximab, [29] and radiation therapy. More recently, topical tacrolimus has been reported of benefit. [30, 31, 32]  Granuloma faciale can also be treated with another topical calcineurin inhibitor, pimecrolimus cream. [33] Dapsone is the oral medication most frequently reported to be of some benefit. [34, 35, 36, 37] Rituximab is a monoclonal antibody against CD-20 approved by the US Food and Drug Administration for treatment of some autoimmune and tumoral diseases.

Next:

Antimicrobial agents

Class Summary

Empiric antimicrobial therapy must be comprehensive and should cover all likely pathogens in the context of the clinical setting.

Dapsone (Avlosulfon)

Dapsone is bactericidal and bacteriostatic against mycobacteria. The mechanism of action is similar to that of sulfonamides where competitive antagonists of PABA prevent formation of folic acid, inhibiting bacterial growth. It has potent anti-inflammatory effects in a variety of skin disorders.

Clofazimine (Lamprene)

Clofazimine is a lipophilic rhimophenazine dye with antimicrobial and anti-inflammatory properties. The mechanism of action is unclear. It affects neutrophils and monocytes by stimulating phagocytosis and the release of lysosomal enzymes and inhibits neutrophil motility and lymphocyte transformation.

Previous
Next:

Calcineurin Inhibitors

Tacrolimus ointment (Prograf)

Tacrolimus reduces inflammation by suppressing the release of cytokines from T cells. It also inhibits transcription for genes that encode IL-3, IL-4, IL-5, GM-CSF, and TNF-alpha, all of which are involved in the early stages of T-cell activation. Additionally, it may inhibit the release of preformed mediators from skin mast cells and basophils and down-regulate the expression of FCeRI on Langerhans cells. It can be used in patients as young as 2 years. Drugs of this class are more expensive than topical corticosteroids. It is available as an ointment in concentrations of 0.03 and 0.1%.

Pimecrolimus (Elidel)

Pimecrolimus is a calcineurin inhibitor; it inhibits T-cell activation and hasa also been shown to inhibit the release of inflammatory mediators from mast cells.

Previous